Insmed (INSM) Amortizatization of Intangibles (2013 - 2026)
Insmed (INSM) posted quarterly Amortizatization of Intangibles of $678000.0 for Q1 2026, little changed year-over-year from $678000.0 in Q1 2025, and little changed quarter-over-quarter from $678000.0 in Q4 2025.
Insmed (INSM) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Insmed's Amortizatization of Intangibles history runs 14 years deep, the most recent figure standing at $678000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles changed 0.0% year-over-year to $678000.0; the TTM figure through Mar 2026 stood at $2.7 million (changed 0.0% YoY), while the FY2025 annual figure was $2.7 million, changed 0.0% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $678000.0, roughly flat from $678000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $729000.0 in Q1 2022, with the low at $114000.0 in Q4 2022.
- The 5-year median for Amortizatization of Intangibles is $678000.0 (2023), against an average of $633764.7.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles sank 99.6% in 2022, then jumped 494.74% in 2023.
- Insmed's Amortizatization of Intangibles stood at $114000.0 in 2022, then surged by 494.74% to $678000.0 in 2023, then changed by 0.0% to $678000.0 in 2024, then changed by 0.0% to $678000.0 in 2025, then changed by 0.0% to $678000.0 in 2026.
- Business Quant data shows INSM's Amortizatization of Intangibles at $678000.0 in Q1 2026, $678000.0 in Q4 2025, and $678000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 678,000.00 |
| Jun 30, 2026 | 678,000.00 |
| Mar 31, 2026 | 678,000.00 |
| Mar 31, 2026 | 678,000.00 |
| Dec 31, 2025 | 678,000.00 |
| Dec 31, 2025 | 678,000.00 |
| Sep 30, 2025 | 678,000.00 |
| Sep 30, 2025 | 678,000.00 |
| Jun 30, 2025 | 678,000.00 |
| Jun 30, 2025 | 678,000.00 |
| Mar 31, 2025 | 678,000.00 |
| Mar 31, 2025 | 678,000.00 |
| Dec 31, 2024 | 678,000.00 |
| Dec 31, 2024 | 678,000.00 |
| Sep 30, 2024 | 678,000.00 |
| Sep 30, 2024 | 678,000.00 |
| Jun 30, 2024 | 678,000.00 |
| Jun 30, 2024 | 678,000.00 |
| Mar 31, 2024 | 678,000.00 |
| Mar 31, 2024 | 678,000.00 |